From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Chemical compound
Ascrinvacumab (PF-03446962 ) is a monoclonal antibody designed for the treatment of cancer.[1]
This drug was developed by Pfizer Inc.
References
Type I
ALK1 (ACVRL1 )ALK2 (ACVR1A )ALK3 (BMPR1A )ALK4 (ACVR1B )ALK5 (TGFβR1 )ALK6 (BMPR1B )
Agonists: BMP (2 , 4 , 5 , 6 , 7 , 8A , 8B , 15 (GDF9B) )Dibotermin alfa Eptotermin alfa GDF (5 (BMP14) , 6 (BMP13) , 7 (BMP12) , 9 , 15 )Radotermin ALK7 (ACVR1C )
Type II
TGFβR2 BMPR2 ACVR2A (ACVR2 )
Agonists: Activin (A , B , AB )BMP (2 , 4 , 5 , 6 , 7 , 8A , 8B , 15 (GDF9B) )Dibotermin alfa Eptotermin alfa GDF (1 , 3 , 5 (BMP14) , 6 (BMP13) , 7 (BMP12) , 9 , 11 (BMP11) , 15 )Myostatin (GDF8) Nodal Radotermin ACVR2B
Agonists: Activin (A , B , AB )BMP (2 , 4 , 6 , 7 )Dibotermin alfa Eptotermin alfa GDF (1 , 3 , 5 (BMP14) , 6 (BMP13) , 7 (BMP12) )Myostatin (GDF8) Nodal Osteogenin (BMP3, BMP3A) Radotermin AMHR2 (AMHR )
Type III
Unsorted
